Ignite Creation Date:
2025-12-24 @ 10:37 PM
Ignite Modification Date:
2025-12-28 @ 7:18 AM
Study NCT ID:
NCT00432835
Status:
COMPLETED
Last Update Posted:
2012-12-03
First Post:
2007-02-07
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D018589', 'term': 'Gastroparesis'}, {'id': 'D009325', 'term': 'Nausea'}, {'id': 'D014839', 'term': 'Vomiting'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}], 'ancestors': [{'id': 'D013272', 'term': 'Stomach Diseases'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D010243', 'term': 'Paralysis'}, {'id': 'D009461', 'term': 'Neurologic Manifestations'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}, {'id': 'D012817', 'term': 'Signs and Symptoms, Digestive'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'tabell@umc.edu', 'phone': '6019844540', 'title': 'Thomas L. Abell, MD, Professor of Medicine', 'organization': 'University of Mississippi Medical Center'}, 'certainAgreement': {'piSponsorEmployee': True}, 'limitationsAndCaveats': {'description': 'New lead implantation techniques now minimize dislodgment (only adverse effect); Parallel, non-crossover protocol will address any carry-over effect after tGES activation OFF; stratification for baseline mucosal EGG and medications may be useful.'}}, 'adverseEventsModule': {'timeFrame': 'Study Days 0-8 (Entirety of Study)', 'eventGroups': [{'id': 'EG000', 'title': 'Gastric Stimactivated', 'description': 'Gastric Electrical Stimulation', 'otherNumAtRisk': 51, 'otherNumAffected': 6, 'seriousNumAtRisk': 51, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Gastric StimulationNotActivated', 'description': 'Sham stimulation', 'otherNumAtRisk': 52, 'otherNumAffected': 7, 'seriousNumAtRisk': 52, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Lead Dislodgment', 'notes': 'All lead dislodgment occurred by Day 4.', 'stats': [{'groupId': 'EG000', 'numAtRisk': 51, 'numEvents': 6, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 52, 'numEvents': 7, 'numAffected': 7}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'Lead Dislodgment'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Symptom of Vomiting Associated With Gastroparesis', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '30', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Gastric Stimactivated Days1-4/Not Activated Days5-8', 'description': 'The sequence followed for patients in Group 1 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal Electrogastrogram, then randomization to Group 1, then active stimulation for 72 consecutive hours, then a 1 day wash out, then the cross over, which entailed the device remaining inactive for the final 3 study days'}, {'id': 'OG001', 'title': 'Gastric StimulationNotActivated Days1-4/Activated Days5-8', 'description': 'The sequence followed for patients in Group 2 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal electrogastrogram, then randomization to Group 2, then no stimulation whatsoever until Day 5, then the cross over,then active stimulation with the Gastric Electrical Stimulator for 72 consecutive hours.'}], 'classes': [{'title': 'Vomiting Score Day 0', 'categories': [{'measurements': [{'value': '1.82', 'spread': '1.55', 'groupId': 'OG000'}, {'value': '2.68', 'spread': '1.61', 'groupId': 'OG001'}]}]}, {'title': 'Vomiting Score Day 3', 'categories': [{'measurements': [{'value': '0.17', 'spread': '0.67', 'groupId': 'OG000'}, {'value': '1.20', 'spread': '1.47', 'groupId': 'OG001'}]}]}, {'title': 'Vomiting Score Day 7', 'categories': [{'measurements': [{'value': '0.91', 'spread': '1.44', 'groupId': 'OG000'}, {'value': '0.72', 'spread': '1.17', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Study Day 0 (Baseline), Day 3, Day 7', 'description': 'Likert Scale 0-4 (low-high) using a patient reported outcomes tool', 'unitOfMeasure': 'Patient Self-reported Symptom Score', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'anticipatedPostingDate': '2010-12'}, {'type': 'PRIMARY', 'title': 'Symptom of Nausea Associated With Gastroparesis', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '30', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Gastric Stimactivated Days1-4/Not Activated Days5-8', 'description': 'The sequence followed for patients in Group 1 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal Electrogastrogram, then randomization to Group 1, then active stimulation for 72 consecutive hours, then a 1 day wash out, then the cross over, which entailed the device remaining inactive for the final 3 study days'}, {'id': 'OG001', 'title': 'Gastric StimulationNotActivated Days1-4/Activated Days5-8', 'description': 'The sequence followed for patients in Group 2 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal electrogastrogram, then randomization to Group 2, then no stimulation whatsoever until Day 5, then the cross over,then active stimulation with the Gastric Electrical Stimulator for 72 consecutive hours.'}], 'classes': [{'title': 'Nause Score Day 0', 'categories': [{'measurements': [{'value': '3.27', 'spread': '0.92', 'groupId': 'OG000'}, {'value': '3.33', 'spread': '1.03', 'groupId': 'OG001'}]}]}, {'title': 'Nausea Score Day 3', 'categories': [{'measurements': [{'value': '1.46', 'spread': '1.29', 'groupId': 'OG000'}, {'value': '1.67', 'spread': '1.49', 'groupId': 'OG001'}]}]}, {'title': 'Nausea Score Day 7', 'categories': [{'measurements': [{'value': '2.26', 'spread': '1.18', 'groupId': 'OG000'}, {'value': '1.4', 'spread': '1.38', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Study Day 0 (Baseline), Day 3, Day 7', 'description': 'Likert Scale 0-4 (low-high) using a patient reported outcomes tool', 'unitOfMeasure': 'Patient Self-reported Symptom Score', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'anticipatedPostingDate': '2010-12'}, {'type': 'PRIMARY', 'title': 'Symptom of Gastric Emptying Time (GET) Associated With Gastroparesis', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '30', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Gastric Stimactivated Days1-4/Not Activated Days5-8', 'description': 'The sequence followed for patients in Group 1 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal Electrogastrogram, then randomization to Group 1, then active stimulation for 72 consecutive hours, then a 1 day wash out, then the cross over, which entailed the device remaining inactive for the final 3 study days'}, {'id': 'OG001', 'title': 'Gastric StimulationNotActivated Days1-4/Activated Days5-8', 'description': 'The sequence followed for patients in Group 2 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal electrogastrogram, then randomization to Group 2, then no stimulation whatsoever until Day 5, then the cross over,then active stimulation with the Gastric Electrical Stimulator for 72 consecutive hours.'}], 'classes': [{'title': 'GET Day 0, at 1st hour', 'categories': [{'measurements': [{'value': '67.07', 'spread': '20.23', 'groupId': 'OG000'}, {'value': '66.13', 'spread': '25.37', 'groupId': 'OG001'}]}]}, {'title': 'GET Day 0, at 2nd hour', 'categories': [{'measurements': [{'value': '69.96', 'spread': '23.79', 'groupId': 'OG000'}, {'value': '37.41', 'spread': '28.06', 'groupId': 'OG001'}]}]}, {'title': 'GET Day 0, at 4th hour', 'categories': [{'measurements': [{'value': '64.71', 'spread': '21.10', 'groupId': 'OG000'}, {'value': '16.43', 'spread': '23.00', 'groupId': 'OG001'}]}]}, {'title': 'GET Day 4, at 1st hour', 'categories': [{'measurements': [{'value': '69.96', 'spread': '23.79', 'groupId': 'OG000'}, {'value': '62.35', 'spread': '24.75', 'groupId': 'OG001'}]}]}, {'title': 'GET Day 4, at 2nd hour', 'categories': [{'measurements': [{'value': '46.85', 'spread': '25.30', 'groupId': 'OG000'}, {'value': '38.00', 'spread': '24.64', 'groupId': 'OG001'}]}]}, {'title': 'GET Day 4, at 4th hour', 'categories': [{'measurements': [{'value': '24.11', 'spread': '23.76', 'groupId': 'OG000'}, {'value': '21.85', 'spread': '28.51', 'groupId': 'OG001'}]}]}, {'title': 'GET Day 8, at 1st hour', 'categories': [{'measurements': [{'value': '64.71', 'spread': '21.10', 'groupId': 'OG000'}, {'value': '68.67', 'spread': '19.92', 'groupId': 'OG001'}]}]}, {'title': 'GET Day 8, at 2nd hour', 'categories': [{'measurements': [{'value': '42.19', 'spread': '24.37', 'groupId': 'OG000'}, {'value': '40.92', 'spread': '26.50', 'groupId': 'OG001'}]}]}, {'title': 'GET Day 8, at 4th hour', 'categories': [{'measurements': [{'value': '24.71', 'spread': '27.94', 'groupId': 'OG000'}, {'value': '20.25', 'spread': '25.26', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Study Day 0 (Baseline), Day 4, Day 8', 'description': "Transit time of a radio-labeled meal through the stomach, measured by scintigraphy for %contents remaining in the stomach at 1 hour, 2 hours, and 4 hours. GET measures were obtained at baseline, during the period allowed for 'washout', and on the final study day.", 'unitOfMeasure': 'percentage of radiolabeled meal in stoma', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'anticipatedPostingDate': '2010-12'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Gastric Stimactivated Days1-4/Not Activated Days5-8', 'description': 'The sequence followed for patients in Group 1 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal Electrogastrogram, then randomization to Group 1, then active stimulation for 72 consecutive hours, then a 1 day wash out, then the cross over, which entailed the device remaining inactive for the final 3 study days'}, {'id': 'FG001', 'title': 'Gastric StimulationNotActivated Days1-4/Activated Days5-8', 'description': 'The sequence followed for patients in Group 2 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal EGG, then randomization to Group 2, then no stimulation whatsoever until Day 5, then the cross over,then active stimulation with the Gastric Electrical Stimulator for 72 consecutive hours.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '28'}, {'groupId': 'FG001', 'numSubjects': '30'}]}, {'type': 'Completed 1st Intervention', 'achievements': [{'groupId': 'FG000', 'numSubjects': '22'}, {'groupId': 'FG001', 'numSubjects': '23'}]}, {'type': 'Completed 2nd Intervention', 'achievements': [{'groupId': 'FG000', 'numSubjects': '22'}, {'groupId': 'FG001', 'numSubjects': '23'}]}, {'type': 'COMPLETED', 'achievements': [{'comment': 'These 22 patients completed the entire 8 day protocol.', 'groupId': 'FG000', 'numSubjects': '22'}, {'comment': 'These 23 patients completed the entire 8 day protocol.', 'groupId': 'FG001', 'numSubjects': '23'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '6'}, {'groupId': 'FG001', 'numSubjects': '7'}]}], 'dropWithdraws': [{'type': 'Adverse event: lead dislodgement.', 'reasons': [{'groupId': 'FG000', 'numSubjects': '6'}, {'groupId': 'FG001', 'numSubjects': '7'}]}]}], 'recruitmentDetails': 'Patients seeking temporary gastric electric stimulator devices for drug-refractory gastroparesis between August 2005 and October 2006 who met the inclusion criteria and did not have any of the exclusion criteria were offered access to the research protocol.', 'preAssignmentDetails': 'No significant events or approaches for the overall study following participant enrollment were performed prior to group assignment.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'BG000'}, {'value': '30', 'groupId': 'BG001'}, {'value': '58', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Gastric Stimactivated Days1-4/Not Activated Days5-8', 'description': 'The sequence followed for patients in Group 1 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal Electrogastrogram, then randomization to Group 1, then active stimulation for 72 consecutive hours, then a 1 day wash out, then the cross over, which entailed the device remaining inactive for the final 3 study days'}, {'id': 'BG001', 'title': 'Gastric StimulationNotActivated Days1-4/Activated Days5-8', 'description': 'The sequence followed for patients in Group 2 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal EGG, then randomization to Group 2, then no stimulation whatsoever until Day 5, then the cross over,then active stimulation with the Gastric Electrical Stimulator for 72 consecutive hours.'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Categorical', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'value': '26', 'groupId': 'BG000'}, {'value': '27', 'groupId': 'BG001'}, {'value': '53', 'groupId': 'BG002'}]}, {'title': '>=65 years', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '5', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Age Continuous', 'classes': [{'categories': [{'measurements': [{'value': '47', 'spread': '13', 'groupId': 'BG000'}, {'value': '47', 'spread': '14', 'groupId': 'BG001'}, {'value': '47', 'spread': '13', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '21', 'groupId': 'BG000'}, {'value': '26', 'groupId': 'BG001'}, {'value': '47', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '7', 'groupId': 'BG000'}, {'value': '4', 'groupId': 'BG001'}, {'value': '11', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'United States', 'categories': [{'measurements': [{'value': '28', 'groupId': 'BG000'}, {'value': '30', 'groupId': 'BG001'}, {'value': '58', 'groupId': 'BG002'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'CROSSOVER'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 58}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2005-08'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2012-11', 'completionDateStruct': {'date': '2007-11', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2012-11-01', 'studyFirstSubmitDate': '2007-02-07', 'resultsFirstSubmitDate': '2012-04-11', 'studyFirstSubmitQcDate': '2007-02-07', 'lastUpdatePostDateStruct': {'date': '2012-12-03', 'type': 'ESTIMATED'}, 'resultsFirstSubmitQcDate': '2012-11-01', 'studyFirstPostDateStruct': {'date': '2007-02-08', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2012-12-03', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2006-10', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Symptom of Vomiting Associated With Gastroparesis', 'timeFrame': 'Study Day 0 (Baseline), Day 3, Day 7', 'description': 'Likert Scale 0-4 (low-high) using a patient reported outcomes tool'}, {'measure': 'Symptom of Nausea Associated With Gastroparesis', 'timeFrame': 'Study Day 0 (Baseline), Day 3, Day 7', 'description': 'Likert Scale 0-4 (low-high) using a patient reported outcomes tool'}, {'measure': 'Symptom of Gastric Emptying Time (GET) Associated With Gastroparesis', 'timeFrame': 'Study Day 0 (Baseline), Day 4, Day 8', 'description': "Transit time of a radio-labeled meal through the stomach, measured by scintigraphy for %contents remaining in the stomach at 1 hour, 2 hours, and 4 hours. GET measures were obtained at baseline, during the period allowed for 'washout', and on the final study day."}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['Nausea', 'Vomiting', 'Delayed gastric emptying', 'Diabetes Mellitus', 'Post-Surgical', 'Idiopathic'], 'conditions': ['Gastroparesis']}, 'referencesModule': {'references': [{'pmid': '21872708', 'type': 'RESULT', 'citation': 'Abell TL, Johnson WD, Kedar A, Runnels JM, Thompson J, Weeks ES, Minocha A, Griswold ME. A double-masked, randomized, placebo-controlled trial of temporary endoscopic mucosal gastric electrical stimulation for gastroparesis. Gastrointest Endosc. 2011 Sep;74(3):496-503.e3. doi: 10.1016/j.gie.2011.05.022.'}], 'seeAlsoLinks': [{'url': 'http://www.ncbi.nlm.nih.gov/pubmed?term=%22Gastrointestinal+endoscopy%22%5BJour%5D+AND+74%5Bvolume%5D+AND+3%5Bissue%5D+AND+496%5Bpage%5D+AND+2011%5Bpdat%5D+AND+Abell%5Bfirst+author%5D+AND+double-masked&TransSchema=title&cmd=detailssearch', 'label': 'Pub Med abstract of study as reported in "Gastrointestinal Endoscopy"'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this research is to determine if temporary gastric electrical stimulation will help improve symptoms of gastroparesis (abnormal stomach emptying). We hypothesize that when the device is ON, Gastrointestinal symptoms will decrease by at least 50% from baseline.', 'detailedDescription': 'Gastric Electrical Stimulation is an established treatment for drug-refractory patients who have the symptoms of gastroparesis/gastropathy. The symptoms of GP are nausea, vomiting, anorexia/early satiety, bloating/distention and abdominal pain and are classically associated with delayed gastric emptying of solids. The technique of GES was first used, in a patient seen at University of Tennesse-Memphis in 1993 and has undergone several clinical trials, particularly the GEMS trial, a feasibility trial starting in 1995 and the WAVESS trial, a double-blind trial begun in 1997. Both were international trials, showing promising results, and both have been published in the last 2 years. However, a number of issues related to who would benefit the most from Gastric Electrical Stimulation therapy have emerged. Among these issues are whether patients with etiologies other than diabetic or idiopathic gastroparesis, such as post-surgical gastropathy, which is often related to rapid, not delayed gastric emptying could be helped.\n\nMost recently a technique for the temporary placement of a Gastric Electrical Stimulation electrode in the stomach with an upper endoscope, combined with an external Gastric Electrical Stimulation device, has been tried and validated, first at UAMS in Little Rock, AR, beginning in 2001 and more recently here at UMMC, beginning later in 2001 and up until the present time. Using the technique of temporary gastric electrical stimulation, we have been able to demonstrate that TempStim can quickly demonstrate (in a manner of days) that a patient will respond to temporary GES, as quantified by a decrease in GI total symptoms and an improvement and normalization in solid gastric emptying.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '70 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Sex: Male of Female\n* Age Range: 18 to 70 inclusive\n* Patients with GP of diabetic, surgically related or idiopathic etiology.\n* Symptoms of GP for \\>/= 1 year.\n* Refractory or intolerant to antiemetic drug classes (antihistamines and phenothiazines, serotonin receptor antagonists, dopamine receptor antagonists)\n* Chronic vomiting and/or nausea with 7 or more episodes per week for either symptom irrespective of GET values.\n* The patient is willing and able to provide informed consent.\n* The patient is willing and able to return for required follow-up visits.\n\nExclusion Criteria:\n\n* Patients \\< 18 or \\>70 years in age.\n* Patients with an active infection of any kind.\n* Patients who the investigator determines are not candidates for endoscopic procedures.\n* Women who are pregnant\n* Inability or unwillingness to provide informed consent\n* Unwilling or unable to return for required follow-up visits and examinations.\n* Patients who are currently enrolled in another investigation of a medical device or drug.'}, 'identificationModule': {'nctId': 'NCT00432835', 'briefTitle': 'Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis', 'organization': {'class': 'OTHER', 'fullName': 'University of Mississippi Medical Center'}, 'officialTitle': 'Double-Blind Placebo-Controlled Cross-Over Design With Wash-Out for Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis', 'orgStudyIdInfo': {'id': '2004-0185'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'Gastric Stimulation Days1-4/Sham5-8', 'description': 'The sequence followed for patients in Group 1 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal EGG, then randomization to Group 1, then active stimulation for 72 consecutive hours, then a 1 day wash out, then the cross over, which entailed the device remaining inactive for the final 3 study days', 'interventionNames': ['Device: Gastric Electrical Stimulator, Enterra, Medtronics, Inc.']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Sham1-4/Gastric Stimulation Days5-8', 'description': 'The sequence followed for patients in Group 2 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal EGG, then randomization to Group 2, then no stimulation whatsoever until Day 5, then the cross over,then active stimulation with the Gastric Electrical Stimulator for 72 consecutive hours.', 'interventionNames': ['Device: Gastric Electrical Stimulator, Enterra, Medtronics, Inc.']}], 'interventions': [{'name': 'Gastric Electrical Stimulator, Enterra, Medtronics, Inc.', 'type': 'DEVICE', 'otherNames': ['No other name currently exists.'], 'description': 'All patients received a GES electrode, endoscopically placed and connected to an external device at baseline. The device was turned ON to provide 72 continuous hours of active stimulation and OFF to deactivate stimulation', 'armGroupLabels': ['Gastric Stimulation Days1-4/Sham5-8', 'Sham1-4/Gastric Stimulation Days5-8']}]}, 'contactsLocationsModule': {'locations': [{'zip': '39216', 'city': 'Jackson', 'state': 'Mississippi', 'country': 'United States', 'facility': 'University of Mississippi Medical Center', 'geoPoint': {'lat': 32.29876, 'lon': -90.18481}}], 'overallOfficials': [{'name': 'Thomas L Abell, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University of Mississippi Medical Center'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'University of Mississippi Medical Center', 'class': 'OTHER'}, 'collaborators': [{'name': 'Medtronic', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Principal Investigator, Professor of Medicine, Director, Division of Digestive Diseases', 'investigatorFullName': 'Thomas Abell, MD', 'investigatorAffiliation': 'University of Mississippi Medical Center'}}}}